TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer. The newly identified targets were initially predicted and selected in silico utilizing the Company’s Monoclonal Antibody Therapeutic Targets Platform and subsequently were experimentally validated. In addition, the Company announced that further experimental validation of the therapeutic potential has been initiated for five of these targets.
